Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,339B 1.54B 1.33B 1.23B 1.15B 2.15B 147B 2.19B 14.5B 5.65B 71.38B 5.79B 5.67B 247B P/E Ratio 2026 *
-74.4x
P/E Ratio 2027 * -91.7x
Enterprise Value 2,339B 1.54B 1.33B 1.23B 1.15B 2.15B 147B 2.19B 14.5B 5.65B 71.38B 5.79B 5.67B 247B EV / Sales 2026 *
292x
EV / Sales 2027 * 187x
Free-Float
82.9%
Yield 2026 *
-
Yield 2027 * -
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-31 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-07 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-01 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-27 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
25-08-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-21 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-10 Lilly, South Korean Drug Maker Partnering to Commercialize Prospective Liver Disease Treatment MT
1 day-7.32%
1 week-22.58%
Current month-34.21%
1 month-26.11%
3 months-41.22%
6 months-12.20%
Current year-17.95%
1 week 112,000
Extreme 112000
143,000
1 month 112,000
Extreme 112000
188,500
Current year 111,800
Extreme 111800
217,000
1 year 34,500
Extreme 34500
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 2010-01-31
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 2022-03-27
Director TitleAgeSince
Director/Board Member 59 2022-03-27
Director/Board Member 53 2021-03-28
Chairman 54 2010-01-31
Date Insider Type Main position Quantity % Market Cap.
25-02-27Fiscal year

Director

30,000 0.1625%
25-02-27Fiscal year

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
-7.32%-22.58%+164.52%+495.66% 1.54B
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +0.89%+1.29%+41.40%+149.89% 21.53B
Weighted average by Cap. +1.66%+2.31%+32.99%+102.61%

Financials

2026 *2027 *
Net sales 8B 5.28M 4.56M 4.2M 3.93M 7.37M 502M 7.48M 49.6M 19.34M 244M 19.81M 19.39M 845M 12.5B 8.25M 7.12M 6.56M 6.14M 11.51M 784M 11.69M 77.5M 30.22M 382M 30.95M 30.29M 1.32B
Net income -31B -20.45M -17.66M -16.28M -15.24M -28.55M -1.94B -29M -192M -74.94M -946M -76.76M -75.12M -3.28B -25B -16.49M -14.25M -13.13M -12.29M -23.03M -1.57B -23.38M -155M -60.43M -763M -61.9M -60.58M -2.64B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
26-06-12 115,200.00 -7.32% 394,971
26-06-11 124,300.00 +0.89% 325,056
26-06-10 123,200.00 -6.45% 362,579
26-06-09 131,700.00 +7.60% 278,056
26-06-08 122,400.00 -17.74% 435,372
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
115,200.00KRW
Average target price
160,000.00KRW
Spread / Average Target
+38.89%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!